Opioid system in L-DOPA-induced dyskinesia

被引：0
作者：
Jing Pan
Huaibin Cai
机构：
[1] Transgenics Section,
[2] Laboratory of Neurogenetics,undefined
[3] National Institute on Aging,undefined
[4] National Institutes of Health,undefined
来源：
Translational Neurodegeneration | / 6卷
关键词：
Basal Ganglion; Opioid Receptor; Opioid Peptide; Globus Pallidus Internal; Opioid Receptor Antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
L-3, 4-Dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) is a major clinical complication in the treatment of Parkinson’s disease (PD). This debilitating side effect likely reflects aberrant compensatory responses for a combination of dopaminergic neuron denervation and repeated L-DOPA administration. Abnormal endogenous opioid signal transduction pathways in basal ganglia have been well documented in LID. Opioid receptors have been targeted to alleviate the dyskinesia. However, the exact role of this altered opioid activity is remains under active investigation. In the present review, we discuss the current understanding of opioid signal transduction in the basal ganglia and how the malfunction of opioid signaling contributes to the pathophysiology of LID. Further study of the opioid system in LID may lead to new therapeutic targets and improved treatment of PD patients.
引用
收藏
相关论文
共 259 条
[41]  
Zimprich A(2005)Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys Neuroscience 132 409-6
[42]  
Biskup S(2005)Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia Ann Neurol 57 17-60
[43]  
Leitner P(2001)Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia Neurobiol Dis 8 220-62
[44]  
Lichtner P(2011)L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry Mol Cell Proteomics 10 009308-13
[45]  
Farrer M(2011)The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson’s disease Mov Disord 26 1225-303
[46]  
Lincoln S(2002)Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease Eur J Neurosci 15 120-30
[47]  
Kachergus J(2001)High dose naltrexone for dyskinesias induced by levodopa J Neurol Neurosurg Psychiatry 70 554-7005
[48]  
Hulihan M(2004)Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson’s disease Mov Disord 19 554-87
[49]  
Uitti RJ(2011)L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission Front Behav Neurosci 5 71-undefined
[50]  
Calne DB(2003)D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson’s disease Neuroscientist 9 455-undefined
12345678910